Molecular Vision: Scheive, Mol Vis 2022; 28:220-229. Table 4

Table 4. Longitudinal linear mixed model of SVC and DVC VD by DR diagnosis and treatment.

OCT-A variable	SVC whole VD			SVC foveal VD			SVC parafoveal VD
	*F-test*	β (95% CI)	*P value*	*F-test*	β (95% CI)	*P value*	*F-test*	β (95% CI)	*P value*
Age	0.41	0.04 (−0.1, 0.1)	0.527	0.03	−0.019 (−0.222, 0.184)	0.850	5.084	0.138 (0.013, 0.264)	0.031*
Diagnosis	2.49		0.088	0.07		0.928	3.712		0.028*
*Mild NPDR*		3.9 (0.1, 7.5)	0.043*		−1.487 (−9.250, 6.276)	0.703		6.126 (1.595, 10.657)	0.009*
*Mod/sev NPDR*		1.3 (−0.6, 3.1)	0.174		−0.38 (−4.5, 3.7)	0.857		1.4 (−0.9,3.7)	0.236
*PDR*		0	-		0	-		0	-
LogMAR	8.69	−4.2 (−7, −1.4)	0.004*	0.01	0.11 (−6.6, 6.8)	0.975	8.801	−5.5 (−9.3, −1.9)	0.004*
Time (months)	0.66	0.04 (−0.1, 0.1)	0.420	2.47	0.2 (−0.1, 0.5)	0.119	1.101	0.08 (−0.06, 0.2)	0.296
Treatment	0.01		0.971	0.73		0.399	0.235		0.631
*Anti-VEGF*		−0.06 (−3.6, 3.5)	0.971		2.7 (−3.7, 9.1)	0.399		−0.93 (−4.8, 3)	0.631
*No treatment*		0	-		0	-		0	-
OCT-A variable	DVC whole VD DVC foveal VD parafoveal VD			DVC foveal VD			DVC parafoveal VD
	*F-test*	β (95% CI)	*P value*	*F-test*	β (95% CI)	*P value*	*F-test*	β (95% CI)	*P value*
Age	8.26	0.12 (0.03, 0.2)	0.007*	0.961	0.095 (−0.1,0.29)	0.335	11.551	0.154 (0.06, 0.25)	0.002*
Diagnosis	1.24		0.297	0.132		0.877	4.283		0.017*
*Mild NPDR*		2.82 (−0.8, 6.5)	0.126		−0.10 (−8.0, 7.8)	0.980		5.63 (1.79, 9.47)	0.005*
*Mod/sev NPDR*		0.82 (−1.2, 2.8)	0.420		1.02 (−3.28, 5.3)	0.637		0.60 (−1.02, 3.19)	0.310
*PDR*		0	-		0	-		0	-
LogMAR	5.38	−4.01 (−7.45, −0.58)	0.022*	3.284	6.5 (−0.6, 13.6)	0.072	1.823	−2.40 (−5.9, 1.1)	0.180
Time (months)	1.780	0.103 (−0.05, 0.25)	0.185	2.148	0.22 (−0.08, 0.51)	0.145	0.593	0.06 (−0.09, 0.2)	0.443
Treatment	3.662		0.063	0.061		0.807	5.060		0.030*
*Anti-VEGF*		−2.58 (−5.30, 0.15)	0.063		−0.76 (−7.02, 5.50)	0.807	0	−3.28 (−6.2, −0.33)	0.030*
*No treatment*		0	-		0	-		0	-